GlassScriptPhysician profile
Thomas J Oconnor
NPI 1891792347
$3,081.57
in general payments reported to CMS, 2019-2025
30 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $215 · 2021: $387 · 2022: $445 · 2023: $259 · 2024: $607 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $557.19 | 2019-2025 | Tryptyr, Rocklatan, Clareon Panoptix Pro |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $317.12 | 2019-2021 | |
| Abbvie INC. | $317.07 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $239.14 | 2019-2024 | Cequa |
| Dompe US, INC. | $196.91 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $170.41 | 2024-2025 | Vevye |
| Rxsight INC | $134.41 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Amgen INC. | $123.72 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $113.94 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $110.08 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $97.38 | 2022-2025 | Vyzulta, Xiidra |
| Horizon Therapeutics Plc | $84.41 | 2020-2022 | |
| Allergan, INC. | $71.57 | 2019-2020 | |
| Thea Pharma INC. | $61.78 | 2023-2025 | Iyuzeh |
| Sight Sciences, INC. | $56.32 | 2022-2024 | Omni Surgical System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $51.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $46.77 | 2019 | |
| Shire North American Group INC | $46.76 | 2019 | |
| Omeros Corporation | $38.19 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $37.71 | 2019-2022 | |
| Ocular Therapeutix, INC. | $36.42 | 2019-2025 | Dextenza |
| Aerie Pharmaceuticals, INC. | $33.94 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $27.62 | 2024 | Cirrus Hd-Oct |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Glaukos Corporation | $17.49 | 2023 | |
| Rayner Intraocular Lenses Limited | $17.30 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Mallinckrodt Hospital Products INC. | $15.16 | 2024 | Acthar |
| New World Medical,INC. | $13.57 | 2022 | |
| Eyepoint US, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.